Cue Biopharma, Inc. (CUE)
After hours:
| Previous close | 2.0800 |
| Open | 2.0900 |
| Bid | 2.1600 x 300 |
| Ask | 2.2000 x 100 |
| Day's range | 2.0750 - 2.2000 |
| 52-week range | 1.3030 - 5.1200 |
| Volume | |
| Avg. volume | 293,609 |
| Market cap | 106.042M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings date | 07 May 2024 - 11 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.40 |
GlobeNewswireCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024. During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress. Presentation Detail
ZacksHere's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- GlobeNewswire
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-
